EVAR术后应用开窗支架移植物矫正IA型内漏:结局与二次失败预测因素
本研究回顾性分析单中心2009年11月至2021年4月连续47例因EVAR后IA型内漏接受开窗支架(FEVAR)矫正的患者,技术成功率96%,无30天死亡,2年免于动脉瘤囊扩张和主动脉相关二次干预分别为80%和69%,术前最大动脉瘤直径是囊扩张的独立预测因素。
要点
- EVAR后迟发IA型内漏可安全采用开窗支架移植物治疗,技术成功率96%。
- 术前最大动脉瘤直径每增加1mm,囊扩张风险HR=1.05,二次干预风险HR=1.07。
- 术前存在IB或III型内漏及原EVAR上方主动脉退变增加二次干预风险。
核心结论
- EVAR后迟发IA型内漏可安全采用开窗支架移植物治疗;术前最大动脉瘤直径与后期动脉瘤囊增长风险增加相关;鉴于再干预率高,该亚组患者必须密切随访。
研究设计与样本
- 回顾性单中心分析前瞻性收集的数据,纳入2009年11月至2021年4月连续接受FEVAR矫正IA型内漏的患者,所有装置由Cook Medical制造。
主要发现
- 共纳入47例患者(89%男性,中位年龄80岁),初始EVAR至FEVAR中位时间60个月[41-72],术前最大动脉瘤直径中位68mm[62-79]。
- 中位透视时间49分钟[36-63],剂量面积乘积66 Gy.cm2[38-101],技术成功率96%,无30天死亡,发生2例(4.3%)肾脏主要不良事件。
- 中位随访22个月[12-36],2年免于动脉瘤囊扩张为80%[66-96],免于主动脉相关二次干预为69%[55-87]。
- 多因素分析显示开窗装置配置不能预测动脉瘤囊扩张,仅术前最大动脉瘤直径是独立预测因素(每增加1mm,HR=1.05[1.01-1.10],p=0.016),并与主动脉相关二次干预风险增高相关(每增加1mm,HR=1.07[1.02-1.12],p=0.006)。
- 主动脉相关二次干预的其他预测因素包括术前存在IB或III型内漏(HR=7.89[1.39-44.8],p=0.020)和原EVAR上方主动脉退变(HR=16.6[1.88-147],p=0.011)。
临床怎么用
- 作者认为,EVAR后迟发IA型内漏可安全采用开窗支架移植物治疗。
- 作者指出,术前最大动脉瘤直径与后期动脉瘤囊增长风险增加相关。
- 作者强调,鉴于再干预率高,该亚组患者必须密切随访。
- 作者在临床影响部分提出,尽管长期结局无显著差异,完全衬里联合分叉型FEVAR可能作为一线方法优先选择,因其可处理隐匿性III型内漏并降低组件脱节风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to review the results of fenestrated stent-graft (Fenestrated Endovascular Aortic Repair [FEVAR]) implantation to treat patients with type IA endoleaks after prior infrarenal endovascular aortic repair (EVAR). METHODS: A retrospective single-center analysis of prospectively collected data was conducted, including consecutive patients who underwent FEVAR to correct a type IA endoleak between November 2009 and April 2021. All devices were manufactured by Cook Medical (INC, Bloomington, Indiana). Demographic details, anatomical features, fenestrated stent-graft configuration, technical success, and major adverse events (MAEs) were recorded according to current SVS standards. The primary endpoint was freedom-from-significant aneurysm sac expansion (≥5 mm) and survival according to the Kaplan-Meier analysis. Secondary endpoints included 30-day outcomes, freedom-from-all-cause mortality, and aortic-related secondary interventions. Multivariate Cox regression was performed to identify factors associated with the study endpoints. RESULTS: Overall, 47 patients (89% male, median age 80) were included. Median time from initial EVAR was 60 months [41-72]. Median pre-FEVAR maximal aneurysm diameter was 68mm [62-79]. Median fluoroscopy time and dose area product were, respectively, 49 min [36-63] and 66 Gy.cm2 [38-101]. Technical success rate was 96% with no 30-day deaths reported. Two (4.3%) renal MAE occurred. Median follow-up was 22 months [12-36]. Two-year freedom-from-aneurysm sac expansion and aortic-related secondary intervention were 80% [66-96] and 69% [55-87], respectively. From the multivariate analysis, the configuration of the fenestrated device was not predictive of aneurysm sac expansion, whereas only the preoperative aneurysm maximal diameter was an independent predictor (hazard ratio [HR] [per 1 mm increment]=1.05 [1.01-1.10]; p=0.016) and was associated with a higher risk of aortic-related secondary intervention (HR [per 1 mm increment]=1.07 [1.02-1.12]; p=0.006). Other predictors of aortic-related secondary intervention were pre-existing type IB or III endoleak (HR=7.89 [1.39-44.8]; p=0.020) and aortic degeneration above the primary EVAR (HR=16.6 [1.88-147], p=0.011). CONCLUSION: Late type IA endoleak after EVAR can be treated safely with a fenestrated stent-graft; preoperative maximum aneurysm diameter is associated with an increased risk of later aneurysm sac growth. Close follow-up is mandatory in this subgroup of patients given the high reintervention rate.Clinical ImpactType IA endoleak following endovascular aneurysm repair (EVAR) can be treated using a fenestrated stent-graft (FEVAR). Treatment options include the addition of a fenestrated cuff alone or complete relining of the previous graft with either a 3-component device or a unibody bifurcated FEVAR. Regardless of the device configuration the treatment appears to be safe but remains associated with high rates of reintervention and aneurysm growth. Although no significant differences have been observed in long-term outcomes, a complete relining with a bifurcated FEVAR may be preferred as a first-line approach, as it offers the advantage of addressing occult associated Type III endoleaks and reducing the risk of component disconnection.
引用
- Mesnard T, Daher M, Patterson BO, et al. Type IA Endoleak Correction With Fenestrated Devices After EVAR: Outcomes and Predictors of Secondary Failure. J Endovasc Ther. 2025. PMID: 39968845. doi:10.1177/15266028251319140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。